These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1295446)

  • 1. A prospective study of tissue polypeptide specific antigen (TPS) in breast cancer diagnosis.
    Eskelinen M; Hippeläinen M; Salmela E; Paajanen H; Alhava E; Syrjänen K
    Anticancer Res; 1992; 12(6B):2033-6. PubMed ID: 1295446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
    Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
    Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E
    Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of a new tumour marker TAG 12 in breast cancer.
    Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P
    Anticancer Res; 1991; 11(2):805-8. PubMed ID: 2064336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer?
    Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E
    Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
    Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
    Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
    Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
    Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CA 15-3, mucin-like carcinoma-associated antigen and tissue polypeptide-specific antigen: correlation to disease state and prognosis in breast cancer patients.
    Cohen AD; Gopas J; Karplus G; Cohen Y
    Isr J Med Sci; 1995; 31(2-3):155-9. PubMed ID: 7744585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients.
    Schuurman JJ; Bong SB; Einarsson R
    Anticancer Res; 1996; 16(4B):2169-72. PubMed ID: 8694538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
    Zheng H; Luo RC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
    Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
    Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new tumor marker MCA in breast cancer diagnosis.
    Eskelinen M; Tikanoja S; Collan Y
    Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
    Eskelinen M; Tikanoja S; Brown J
    Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor markers MCA and CA-125 in the diagnosis and monitoring of breast cancer].
    Shakhtarin VV; Izotova IA; Parshkov EM; Chekin SIu; Simakova GM
    Vopr Onkol; 1992; 38(4):433-9. PubMed ID: 1300737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
    Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
    Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.